GSK's Blenrep Shows 50% Risk Reduction in Multiple Myeloma Trial

Jun 2, 2024, 12:25 PM

At the ASCO24 conference, GlaxoSmithKline (GSK) presented promising results for its blood cancer drug, Blenrep, in the Phase 3 DREAMM-8 trial. The trial, which involved 302 patients, showed that Blenrep, when combined with pomalidomide and dexamethasone, significantly reduced the risk of disease progression or death by nearly 50% in patients with relapsed or refractory multiple myeloma. This combination resulted in a 20 percentage point higher one-year progression-free survival compared to a regimen including bortezomib. These findings could pave the way for Blenrep's return to the market after it was previously withdrawn following a trial failure.